<div id="readability-page-1"><p>Sanara MedTech (NASDAQ:SMTI - Get Free Report) will likely be releasing its  Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $26.80 million for the quarter. Investors may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:00 AM ET.</p><p>Sanara MedTech (NASDAQ:SMTI - Get Free Report) last posted its earnings results on Tuesday, March 24th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.07). Sanara MedTech had a negative net margin of 36.42% and a negative return on equity of 20.73%. The firm had revenue of $27.55 million during the quarter, compared to analyst estimates of $27.90 million. </p><div><p><span></span><span>Get <strong>Sanara MedTech</strong> alerts:</span></p></div><h2>Sanara MedTech Trading Up 3.4%</h2><p>NASDAQ SMTI traded up $0.65 during trading hours on Tuesday, reaching $19.64. The company had a trading volume of 10,722 shares, compared to its average volume of 58,997. The company has a current ratio of 1.80, a quick ratio of 1.59 and a debt-to-equity ratio of 7.75. The stock has a market capitalization of $180.00 million, a P/E ratio of -4.64 and a beta of 1.16. The stock has a 50-day moving average of $18.89 and a 200 day moving average of $21.95. Sanara MedTech has a 1-year low of $16.05 and a 1-year high of $35.95. </p><h2>Institutional Trading of Sanara MedTech</h2><p>A number of institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets boosted its stake in  Sanara MedTech by 351.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,504 shares of the company's stock valued at $48,000 after purchasing an additional 1,171 shares during the period.  Wells Fargo &amp; Company MN lifted its holdings in shares of  Sanara MedTech by 78.1% in the 4th quarter. Wells Fargo &amp; Company MN now owns 3,322 shares of the company's stock worth $78,000 after acquiring an additional 1,457 shares during the last quarter.  Lazard Asset Management LLC boosted its stake in shares of  Sanara MedTech by 63,100.0% in the 2nd quarter. Lazard Asset Management LLC now owns 3,160 shares of the company's stock valued at $89,000 after purchasing an additional 3,155 shares in the last quarter.  Deutsche Bank AG grew its holdings in shares of  Sanara MedTech by 171.1% during the 4th quarter. Deutsche Bank AG now owns 3,985 shares of the company's stock valued at $93,000 after purchasing an additional 2,515 shares during the last quarter.  Finally, Bank of America Corp DE raised its position in  Sanara MedTech by 44.1% in the 3rd quarter. Bank of America Corp DE now owns 3,181 shares of the company's stock worth $101,000 after purchasing an additional 973 shares during the period. Institutional investors and hedge funds own  8.10% of the company's stock. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Several research firms have weighed in on SMTI. HC Wainwright  reaffirmed a &#34;buy&#34; rating and issued a $36.00 target price on shares of Sanara MedTech in a research report on Monday, January 26th. Lake Street Capital began coverage on Sanara MedTech in a research report on Wednesday, April 15th. They set a &#34;buy&#34; rating and a $32.00 price objective on the stock. Weiss Ratings  reiterated a &#34;sell (e+)&#34; rating on shares of Sanara MedTech in a research note on Tuesday, April 21st. Wall Street Zen downgraded Sanara MedTech from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Sunday, April 5th. Finally, Zacks Research cut Sanara MedTech from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, January 20th. Two equities research analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has assigned  a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of &#34;Hold&#34; and a consensus target price of $34.00.</p><p><b>Get Our Latest Stock Analysis on Sanara MedTech</b></p><h2>About Sanara MedTech</h2> (Get Free Report)<p>Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company's core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.  </p><p>With its legacy rooted in the assets of a former Johnson &amp; Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Sanara MedTech</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U01USQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U01USQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Sanara MedTech Right Now?</h2><p>Before you consider Sanara MedTech, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanara MedTech wasn't on the list.</p><p>While Sanara MedTech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SMTI

<p>Sanara MedTech (NASDAQ: SMTI) is set to release its Q1 2026 earnings on May 12, with analysts predicting a loss of $0.13 per share and revenue of $26.80 million. The company previously reported earnings of $0.04 per share, missing estimates. Institutional investors have increased their stakes, and analysts have mixed ratings on the stock, with an average rating of "Hold" and a target price of $34.00. Sanara MedTech specializes in medical technology for ENT healthcare, focusing on innovative sinus dilation systems.</p>

Market Beat

Sanara Medtech

BNP Paribas

Wells Fargo

Lazard

Deutsche Bank AG

Bank of America

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Sanara MedTech (SMTI) Projected to Post Earnings on Tuesday